Endo Buys Par Pharma for $8.05 Billion Amid Hunt for Deals

Updated on

Inside the Endo Deal to Buy Par Pharma for $8.05B

Endo International Plc, the maker of pain drugs like Opana and Percocet, agreed to buy Par Pharmaceutical Holdings Inc. for $8.05 billion as part of a plan to ignite sales growth and pursue more acquisitions.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.